- Welcome and Introduction
- Testing platforms and assays for the detection of gene fusions and mutations
- Tissue availability challenges
- Choice of primary site versus metastatic site
- Best practices for sample collection
- Importance of knowing both molecular biomarker variants and PD-L1 status before selecting treatment
- Interpreting biomarker assay results and determining how results should affect therapeutic planning and/or clinical trial enrollment
- Importance of communication among the multidisciplinary team
- Overcoming barriers to reflexive testing of emerging molecular biomarkers in appropriate biopsies
- Investigational biomarker assessment and key ongoing clinical trials
- Question and Answer Session
Date / Time
Matthew Gubens, MD, MS
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California
Alexander Mackinnon, MD, PhD
Director, Division of Genomics Diagnostics and Bioinformatics
Department of Pathology
School of Medicine
University of Alabama at Birmingham
This program will provide expert faculty perspectives and recommendations on the optimal testing approaches for biomarkers and contextualize the assessment and application of actionable biomarkers to effectively and safely integrate novel and emerging targeted therapies into clinical practice for the personalization of care for patients with non-small cell lung cancer.
The goal of this program is to improve the knowledge, confidence, and competence of learners in the use of biomarkers to select individualized treatments for patients with NSCLC.
This program is intended for pathologists, oncologists and other healthcare providers who care for patients with lung cancer.
Upon completion of this activity, participants should be able to:
- Assess current molecular biomarker guideline recommendations along with new and emerging predictive biomarkers to guide precision treatment decisions in patients with NSCLC
- Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, and other nuances
- Identify clinically appropriate testing for all appropriate currently available biomarkers to guide treatment selection and clinical trial eligibility for patients with NSCLC
- Summarize the available data and expert recommendations to determine which biomarkers should be tested in patients with lung cancer
- Identify best practices and strategies for interdisciplinary collaboration/coordination among pathologists and oncologists, regarding cancer biomarker testing and interpretation of results to guide clinical decisions
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Designation of Credit
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
American Board of Pathology Continuing Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Lifelong Learning point in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.